Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01338012 · ClinicalTrials.gov registry record · Phase 2
Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer
A Phase 2 study, sponsored by Dendreon.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT01338012: Clinical Trial Phase 2 study, sponsored by Dendreon.
NCT01338012 is a Phase 2 study that was terminated before completion, run by Dendreon. The registered enrollment target is 8 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01338012, a Phase 2 study, was terminated before completion, sponsored by Dendreon.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
Multicenter open label, uncontrolled study that enrolled men with metastatic castrate resistant prostate cancer previously treated with sipuleucel-T in the androgen dependent setting in the Dendreon P-11 study. The study was divided into Active and Long Term Follow-up (LTFU) Phases.
Primary Outcome
Number of study participants that were enrolled and treated in this trial following completion of study P-11 and prior to study termination.
Interventions
- BIOLOGICAL sipuleucel-T
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2011-12 |
| Est. Completion | 2015-04 |
| Phase | Phase 2 |
Why NCT01338012 stopped before completion
NCT01338012 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which sipuleucel-T is the first listed.
NCT01338012 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01338012 about?
NCT01338012 is a clinical study titled "Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer". Multicenter open label, uncontrolled study that enrolled men with metastatic castrate resistant prostate cancer previously treated with sipuleucel-T in the androgen dependent setting in the Dendreon P-11 study. The study was divided into Active and Long Term Follow-up (LTFU) Phases.
What is the current status of trial NCT01338012?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2011-12. Estimated completion is 2015-04.
What interventions are being tested in trial NCT01338012?
The interventions under investigation include: sipuleucel-T (BIOLOGICAL).
Who is sponsoring clinical trial NCT01338012?
This trial is sponsored by Dendreon, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01338012's enrollment target sits among peer trials
8 1990th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia